# Nuclide record nct05939414 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct05939414/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct05939414", "NCT05939414" ;
  schema:name "An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC."@en ;
  schema:description "A phase 3 trial of FAP-2286 in prostate cancer, run by Novartis Pharmaceuticals, now recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct05939414/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05939414> ;
  nuclide:status "recruiting" ;
  nuclide:tag "ctgov-ingest" ;
  nuclide:phase "3" ;
  nuclide:related <https://nuclide.cc/isotopes/f-18/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:drugs <https://nuclide.cc/drugs/fap-2286/> ;
  nuclide:companies <https://nuclide.cc/companies/novartis/> .